1. Over the Counter (OTC) Drugs & Dietary Supplements Market Global Opportunity Analysis and Industry Forecast, 2017-2023

2. Overview :. Global Over The Counter (OTC) Drugs & Dietary Supplements Market was valued at $223 billion in 2016, and is expected to reach $335 billion by 2023, registering a CAGR of 5.9% from 2017 to 2023. OTC drugs are also known as non-prescription medicines, as these can be availed without prescriptions. OTC medicines are safe if they are administered according to the instructions provided by healthcare professionals. However, dietary supplements contain dietary ingredients, which are used to provide nutrients to the body to fulfill the nutrient balance of the body. In addition, they provide non-nutrient chemicals, which provide biological benefit to the body. Development of strong regulatory policies governing the sale of OTC drugs and the focus of manufacturers to adhere to higher quality standard and correct branding and labeling of dietary supplements have intensified their interest in the marketing of these products. All these factors are anticipated to give impetus to the market across the globe

3. The research report is prepared with extensive inputs from a wide range of market participants that include business executives, product managers, clinical specialists, healthcare organizations, and leading trade associations. The report provides in-depth analysis of the current and emerging trends, key drivers and restraining factors, changes in regulatory landscape and their impact on competitive dynamics, and strategies adopted by the leading market players. Key Benefits The study provides an in-depth analysis of the global over the counter (OTC) drugs & dietary supplements market along with the current trends and future estimations to elucidate the imminent investment pockets. A quantitative analysis from 2016 to 2023 is discussed to enable stakeholders to capitalize on the prevailing market opportunities. Key market players are profiled and their strategies are thoroughly analyzed to understand the competitive outlook of the industry. Porters five forces model is expected to interpret the impact of bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players on the market growth.

4.  Over the counter (OTC) drugs are non-prescription medicines, which are sold directly to consumers without any prescription from doctors and other healthcare professionals. The OTC drugs are regulated by governmental bodies to ensure that the ingredients used are safe and effective for use without a physician's supervision.  These drugs are regulated by active pharmaceutical ingredients (APIs) not final product. Dietary supplements are intended to provide nutrients to increase the quantity of consumption or provide non- nutrient chemicals that have biologically beneficial effects to users.  These supplements are available across all distribution channels such as pharmacies, grocery stores, shopping marts, online pharmacies, and other retailers. The global over the counter (OTC) drugs & dietary supplements market was valued at $223 billion in 2016, and is expected to reach at $335 billion by 2023, registering a CAGR of 5.9% from 2017 to 2023.

5. Segmentation By Category Vitamin & Dietary Supplements Cough & Cold Products Analgesics Gastrointestinal Products Sleep Aids Otic Products Wart Removers Mouth Care Products Ophthalmic Products Botanicals Antacids Smoking Cessation Products Feminine Care Others By Dosage Form Tablets Hard Capsules Powders Ointments Soft Capsules Liquids Others By Product Branded Drugs Generic Drugs By Distribution Channel Pharmacies Grocery Stores Vitamin & Health Food Stores Online Pharmacy Others

6. NORTH AMERICA EUROPE LAMEA ASIA-PACIFIC BY GEOGRAPHY

7. Download the full report: https://www.alliedmarketresearch.com/request-sample/2695 The report provides a comprehensive analysis of the key players operating in the global market such as Pfizer Inc., Novartis International AG, Roche Holding AG, Merck & Co., Inc., Sanofi S.A, Johnson & Johnson, Gilead Sciences, GlaxoSmithKline plc., Bayer Healthcare AG, AstraZeneca plc.

8. Thank You! For More Details Visit us at https://www.alliedmarketresearch.com